Translational Research, Department of Pharmacokinetics, Dynamics and Metabolism, Pfizer PGRD, Sandwich, Kent CT13 9NJ, UK.
Drug Discov Today. 2012 Jul;17(13-14):665-70. doi: 10.1016/j.drudis.2012.01.015. Epub 2012 Jan 25.
The pharmaceutical industry is in the process of re-inventing its pipeline in an attempt to overcome its increasing phase II and III attrition rates. Here, we describe how systems pharmacology can be used as a risk assessment tool to alleviate this problem before bringing in larger investments. We propose that this translational research tool could provide a valuable, complementary addition to other emerging innovative approaches for target identification and validation in discovery and, ultimately, for aiding clinical trial optimization.
制药行业正在重新调整其研发管线,试图克服不断增加的 II 期和 III 期淘汰率。在这里,我们描述了系统药理学如何在投入更大的资金之前作为一种风险评估工具来缓解这个问题。我们提出,这种转化研究工具可以为发现阶段的其他新兴创新方法(包括靶点识别和验证)提供有价值的补充,最终还可以帮助优化临床试验。